Uterine papillary serous carcinoma: State of the state

Current Oncology Reports

Volumn 10, Issue 6, 2008, Pages 505-511

  Naumann, R Wendel ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADJUVANT THERAPY; BRACHYTHERAPY; CANCER INVASION; CANCER MORPHOLOGY; CANCER RECURRENCE; CANCER STAGING; CLEAR CELL CARCINOMA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; GENE EXPRESSION PROFILING; HUMAN; HYSTERECTOMY; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; POSTMENOPAUSE; PROGNOSIS; RECURRENCE RISK; REVIEW; SURGICAL TECHNIQUE; UTERINE PAPILLARY SEROUS CARCINOMA; UTERUS CARCINOMA;

ANTINEOPLASTIC AGENTS; BIOPSY; CLINICAL TRIALS AS TOPIC; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MEDICAL ONCOLOGY; RECURRENCE; RESEARCH DESIGN; RISK; UTERINE NEOPLASMS;

EID: 58649086244     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0076-x     Document Type: Review

References (41)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57: 43-66.
2. Hendrickson M, Ross J, Eifel P, et al.: Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982, 6: 93-108.
3. Gusberg SB: Precursors of Eorpus carcinoma: estrogens and adenomatous hyperplasia. 1947. CA Cancer J Clin 1989, 39: 179-192.
4. Way S: The aetiology of carcinoma of the body of the uterus. J Obstet Gynaecol Brit Emp 1954, 1: 46-58.
5. Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15: 10-17.
6. Mutter GL, Baak JP, Fitzgerald JT, et al.: Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 2001, 83: 177-185.
7. Zheng W, Liang SX, Yu H, etAal.: Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: Morphologic features. Int J Surg Pathol 2004, 12: 207-223.
8. Hamilton CA, Cheung MK, Osann K, et al.: Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006, 94: 642-646.
9. Sherman ME, Bitterman P, Rosenshein NB, et al.: Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992, 16: 600-610.
10. Ambros RA, Sherman ME, Zahn CM, et al.: Endometrial intraepithelial carcinoma: A distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995, 26: 1260-1267.
11. Slomovitz BM, Burke TW, Eifel PJ, et al.: Uterine papillary serous carcinoma (UPSC): A single institution review of 129 cases. Gynecol Oncol 2003, 91: 463-469.
12. Zheng W, Liang SX, Yi X, et al.: Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol 2007, 26: 38-52.
13. Goff BA, Kato D, Schmidt RA, et al.: Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994, 54: 264-268.
14. Sherman ME, Bur ME, Kurman RJ: P53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis. Hum Pathol 1995, 26: 1268-1274.
15. Carcangiu ML, Tan LK, ChamberA JT: Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol 1997, 21: 1507-1514.
16. Bur ME, Perlman C, Edelmann L, et al.: P53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992, 98: 81-87.
17. Santin AD, Zhan F, Cane S, et al.: Gene expression fingerprint of uterine serous papillary carcinoma: Identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer 2005, 92: 1561-1573.
18. Slomovitz BM, Broaddus RR, Burke TW, et al.: Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004, 22: 3126-3132.
19. Kelly MG, O'Malley DM, Hui P, et al.: Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005, 98: 353-359.
20. Geisler JP, Geisler HE, Melton ME, Wiemann MC: What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol 1999, 74: 465-467.
21. Chan JK, Loizzi V, Youssef M, et al.: Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 2003, 90: 181-185.
22. Creasman WT, Kohler MF, Odicino F, et al.: Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004, 95: 593-596.
23. McMeekin DS, Filiaci VL, Thigpen JT, et al.: The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in fir-stline chemotherapy trials: A Gynecologic Oncology Group study. Gynecol Oncol 2007, 106: 16-22.
24. Keys HM, Roberts JA, Brunetto VL, et al.: A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004, 92: 744-751. [Published erratum appears in Gynecol Oncol 2004, 94:241-242.]
25. Havrilesky LJ, Secord AA, Bae-Jump V, et al.: Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 2007, 105: 677-682.
26. Goldberg H, Miller RC, Abdah-Bortnyak R, et al.: Outcome after combined modality treatment for uterine papillary serous carcinoma: A study by the Rare Cancer Network (RCN). Gynecol Oncol 2008, 108: 298-305.
27. Huh WK, Powell M, Leath CA 3rd, et al.: Uterine papillary serous carcinoma: Comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Gynecol Oncol 2003, 91: 470-475.
28. Hogberg T, Rosenberg P, Kristensen G, et al.: A randomized phase-III study on adjuvant treatment with radiation ± chemotherapy in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991 [abstract]). J Clin Oncol 2007, 25: 5503.
29. Randall ME, Filiaci VL, Muss H, et al.: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2006, 24: 36-44.
30. Bristow RE, Duska LR, Montz FJ: The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001, 81: 92-99.
31. Smith RS, Kapp DS, Chen Q, Teng NN: Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int J Radiat Oncol Biol Phys 2000, 48: 767-778.
32. Sutton G, Axelrod JH, Bundy BN, et al.: Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: A gynecologic oncology group study. Gynecol Oncol 2005, 97: 755-763.
33. Homesley HD, Filiaci VL, Gibbons SK, et al.: Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study [abstract]. Presented at the 39th Annual Meeting of the Society of Gynecologic Oncologists. Tampa, FL; March 9, 2008. Gynecol Oncol 2008, 108:S1.
34. Fleming GF, Brunetto VL, Cella D, et al.: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2004, 22: 2159-2166.
35. Levenback C, Burke TW, Silva E, et al.: Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol 1992, 46: 317-321.
36. Price FV, Chambers SK, Carcangiu ML, et al.: Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol 1993, 51: 383-389.
37. Ramondetta L, Burke TW, Levenback C, et al.: Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol 2001, 82: 156-161.
38. Hoskins PJ, Swenerton KD, Pike JA, et al.: Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001, 19: 4048-4053.
39. Zanotti KM, Belinson JL, Kennedy AW, et al.: The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1999, 74: 272-277.
40. Vaidya AP, Littell R, Krasner C, Duska LR: Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer 2006, 16(Suppl 1): 267-272.
41. Chambers JT, Chambers SK, Kohorn EI, et al.: Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. Gynecol Oncol 1996, 60: 438-442.